$ProShares Ultra纳斯达克生物科 (BIB.US)$was climbing 1.5%. $SciSparc (SPRC.US)$rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing. $Glaukos (GKOS.US)$gained 6% after We...
Glaukos股票讨论
$Arcutis Biotherapeutics (ARQT.US)$ : 批准日期为12/15
• ZORYVE® (0.3%环丙沙星泡沫)
顶级泡沫
PDUFA:12/16/23
⇒ NDA
脂溢性皮炎
$默沙东 (MRK.US)$ :已批准 12/15
• KEYTRUDA( 用于癌症治疗的pembrolizumab)+ Padcev(用于癌症治疗的enfortumab vedotin-ejfv)
⇒ 静脉注射
⇒ PDUFA:05/09/24
⇒ sBLA
⇒ 尿路上皮癌
$Glaukos (GKOS.US)$ : 于12/14获批
• 爱文思控股 TR(曲普洛司特)
⇒ 眼内植入物
⇒ PDUFA:12/22/23
⇒ NDA
⇒ 青光眼
$默沙东 (MRK.US)$ : 已批准 ...
加入我们以互相连接和分享,并快速获取信息!
$CRISPR Therapeutics (CRSP.US)$ $福泰制药 (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $安进 (AMGN.US)$ $默沙东 (MRK.US)$
我在这里看到了一些不错的图表上涨
有什么想法?
$SciSparc (SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos (GKOS.US)$ gained 6% after We...
• $Canoo (GOEV.US)$ +71.3%(从沃尔玛获得4500辆Canoo电动交付车的订单)
• $Aldeyra Therapeutics (ALDX.US)$ +14.1%(在干眼病室内交叉试验中达到主要终点)
• $西港燃料 (WPRT.US)$ +10.9%(获得 3800 万美元计划奖励)
• $Greenwich LifeSciences (GLSI.US)$ +5.9%(FDA 撤销了临床暂停,允许 Flamingo-01 第三期临床试验继续...
暂无评论